India's Rs 10,000 crore biopharma shakti scheme, cancer drug relief and more

Despite health allocations crossing Rs 1 lakh crore, nearly half of Indians still avoid government healthcare facilities—a paradox highlighted by veteran health editor Sneha Mordani on Health360. She pointed to public distrust driven by staff shortages and uneven quality of care. The programme examined the Rs 10,000 crore Biopharma Shakti scheme, aimed at transforming India from a generics powerhouse into a global pharma innovation hub. It also noted the exemption of 17 essential cancer drugs from customs duty, reducing treatment costs. The show featured an AIIMS Delhi study using speech analysis to detect depression with 75% accuracy and warned about cancer-linked "forever chemicals" in common household products.